How to Get Jardiance in Washington: Prescriptions, Telehealth, and Pharmacy Guide

What Is Jardiance and Why Do Washington Patients Seek It?

Jardiance is the brand name for empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by Boehringer Ingelheim and Eli Lilly. It blocks glucose reabsorption in the proximal tubule of the kidney, lowering blood sugar while promoting caloric loss through glycosuria. Beyond glycemic control, the drug demonstrated a 38% relative risk reduction in cardiovascular death in the landmark EMPA-REG OUTCOME trial (N=7,020, median follow-up 3.1 years) published in the New England Journal of Medicine in 2015. [1]

The FDA has approved empagliflozin for three distinct indications: type 2 diabetes mellitus, heart failure (both reduced and preserved ejection fraction), and chronic kidney disease (CKD) to slow eGFR decline. [2] Washington state has a high prevalence of type 2 diabetes, with the CDC estimating that approximately 8.4% of Washington adults carry a diagnosed diabetes diagnosis. [3] That burden, combined with the drug's proven cardiovascular and renal benefits, explains why searches for "how to get Jardiance in Washington" have grown substantially over the past two years.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo over a median of 16 months. [4] The EMPA-KIDNEY trial (N=6,609) then extended those findings to CKD, showing a 28% reduction in the composite of kidney disease progression or cardiovascular death. [5] These results cemented empagliflozin as a first-line agent across multiple guidelines, including the 2023 American Diabetes Association Standards of Care. [6]

Who Can Prescribe Jardiance in Washington State?

Any licensed prescriber with authority to write Schedule V or non-controlled prescriptions in Washington can prescribe empagliflozin. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Washington is a full-practice-authority state for NPs. Under RCW 18.79, licensed advanced registered nurse practitioners (ARNPs) can prescribe independently without a physician collaborative agreement. [7] PAs in Washington operate under a delegation agreement with a supervising physician per RCW 18.71A, which means a PA can prescribe Jardiance as long as empagliflozin falls within the delegated scope. [8] In practice, most primary care PAs and endocrinology PAs routinely prescribe SGLT2 inhibitors.

Telehealth providers must hold a Washington state license or a temporary practice permit. The Washington State Department of Health does not require a prior in-person visit before a telehealth prescriber issues a new non-controlled prescription, which makes it straightforward for a qualifying patient to complete an asynchronous or synchronous online visit and receive a Jardiance prescription the same day. [9]

How to Get a Jardiance Prescription in Washington: Step-by-Step

Getting empagliflozin in Washington follows a predictable sequence whether you use an in-person clinic or a telehealth platform.

Step 1: Identify a qualifying indication. Jardiance is FDA-approved for type 2 diabetes, heart failure (HFrEF or HFpEF with LVEF <45% or <60% depending on trial criteria), and CKD with eGFR 20-45 mL/min/1.73m². A prescriber will confirm which indication applies to you. [2]

Step 2: Order baseline labs. Before initiating empagliflozin, your provider needs a current basic metabolic panel (BMP) including serum creatinine, an estimated GFR, and ideally a UACR. The 2023 ADA Standards of Care specifically recommend eGFR and UACR assessment at initiation and then annually. [6] Patients with eGFR <20 mL/min/1.73m² should not start the drug because glycemic efficacy is minimal and the risk profile shifts.

Step 3: Schedule a visit. In-person appointments at a primary care office, endocrinology clinic, cardiology practice, or nephrology practice all work. Telehealth platforms licensed in Washington can conduct a synchronous video visit or process an asynchronous intake form and generate a prescription electronically. The Washington Telehealth Act (RCW 74.09.325) requires that telehealth services meet the same standard of care as in-person visits. [9]

Step 4: Receive the e-prescription. Washington participates in the national e-prescribing infrastructure. A prescriber sends the Jardiance order electronically to any Washington-licensed pharmacy or mail-order pharmacy that ships to Washington addresses.

Step 5: Insurance verification or PA submission. If you carry commercial insurance or Washington Apple Health (Medicaid), the pharmacy runs an adjudication check. Many commercial plans cover Jardiance at tier 2 or tier 3. Apple Health requires prior authorization; see the dedicated PA section below.

Step 6: Fill at a local or mail-order pharmacy. Most major retail chains (Walgreens, CVS, Rite Aid, Bartell Drugs) and mail-order services (Express Scripts, Optum Rx, Amazon Pharmacy) fill empagliflozin in Washington. A 90-day supply via mail order typically reduces out-of-pocket cost.

Labs Required Before Jardiance in Washington

Three lab values drive the prescribing decision for empagliflozin. None of these is optional under current guideline-based practice.

eGFR. The FDA label and the 2022 KDIGO CKD guidelines both specify eGFR thresholds for dosing and contraindication. [2][10] Jardiance is not expected to improve glycemic control when eGFR falls below approximately 30 mL/min/1.73m², though the CKD indication extends use to eGFR as low as 20 mL/min/1.73m² for renoprotection.

Serum potassium and sodium (from BMP). SGLT2 inhibitors can mildly shift electrolytes. A baseline BMP identifies patients with pre-existing hyponatremia or hyperkalemia who need closer monitoring.

UACR. A urine albumin-to-creatinine ratio above 200 mg/g identifies patients most likely to benefit from empagliflozin's renoprotective effects and is used to justify prior authorization on many Washington commercial plans and Apple Health.

Some prescribers also check a baseline HbA1c (required for diabetes indication PA), a fasting lipid panel, and a urinalysis to rule out active urinary tract infection before starting. [6] Patients with recurrent genital mycotic infections or a history of Fournier's gangrene should discuss risk-benefit with their provider before initiating.

Telehealth Providers Prescribing Jardiance in Washington

Several telehealth platforms hold Washington state licenses and can prescribe empagliflozin. Washington's telehealth law does not mandate an in-person visit before a new chronic-disease prescription, giving patients in rural counties the same access as Seattle-area residents.

A synchronous video visit typically runs 20-30 minutes for a new empagliflozin consultation. The prescriber reviews lab results (which the patient may upload or order through a partner lab), confirms the indication, checks contraindications, and sends an e-prescription. Asynchronous platforms allow the patient to submit a medical history form and lab results; a provider reviews within 24-48 hours and issues the prescription if appropriate.

The HealthRX clinical team uses a three-gate framework for telehealth Jardiance evaluation in Washington:

1. Indication gate. Confirmed type 2 diabetes (HbA1c >6.5% on two occasions or fasting glucose >126 mg/dL), documented HFrEF/HFpEF, or CKD with eGFR 20-45 mL/min/1.73m² and UACR >200 mg/g.
2. Safety gate. eGFR >20 mL/min/1.73m², no active UTI, no active foot ulcer or lower-limb amputation risk factors that are unmanaged, not pregnant.
3. Drug interaction gate. Review of concurrent loop diuretics (volume depletion risk), insulin or sulfonylureas (hypoglycemia risk with combination), and NSAIDs (additive renal stress).

Patients who clear all three gates receive a 10 mg once-daily starting prescription with a 90-day follow-up plan including repeat eGFR and BMP.

Prior Authorization for Jardiance Under Washington Apple Health (Medicaid)

Washington Apple Health covers empagliflozin for type 2 diabetes, heart failure, and CKD, but the coverage requires prior authorization (PA) in nearly all managed care plans. The PA criteria align with the FDA label, but documentation requirements are specific.

For the type 2 diabetes indication, Apple Health managed care organizations (MCOs) generally require:

• Confirmed diagnosis (ICD-10 code E11.xx)
• HbA1c of 7.0% or higher documented within the past 90 days
• Trial or contraindication to metformin (metformin is required as first-line unless contraindicated)
• Prescriber attestation that the patient has cardiovascular disease, CKD, or heart failure, which are factors that make SGLT2 inhibitor use preferred by the 2023 ADA Standards of Care [6]

For the heart failure indication, most MCOs require an echocardiogram report documenting LVEF and NYHA functional class II-IV.

For the CKD indication, documentation of two eGFR values at least 90 days apart both below 60 mL/min/1.73m², plus a UACR above 200 mg/g, satisfies most Apple Health PA criteria.

The American Diabetes Association's Standards of Medical Care in Diabetes 2023 state: "In patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, an SGLT2 inhibitor... with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or hospitalization for heart failure." [6] Citing this language directly in a PA appeal frequently accelerates approval.

Commercial plan PA requirements in Washington vary by insurer. Premera Blue Cross, Regence BlueShield, and Kaiser Permanente Washington each publish preferred drug lists (PDLs) and PA criteria on their formulary portals. Prescribers or clinical staff submit PA requests via CoverMyMeds or directly through each insurer's provider portal. Typical PA turnaround is 3-5 business days for standard review and 24-72 hours for urgent review.

Jardiance Costs and Savings Programs in Washington

The list price for a 30-tablet supply of Jardiance 10 mg is approximately $650 without insurance. Boehringer Ingelheim offers the Jardiance Savings Card for commercially insured patients, which can reduce the copay to as low as $10 per month. The savings card is not valid for Medicare Part D or Medicaid beneficiaries. [11]

Patients on Medicare Part D who hit the catastrophic coverage threshold pay no more than $35 per month for insulin under the Inflation Reduction Act, but Jardiance is not insulin, so the $35 cap does not apply. Medicare Part D Extra Help (Low Income Subsidy) can substantially reduce costs for qualifying low-income beneficiaries.

Generic empagliflozin is not yet available in the United States. The Boehringer Ingelheim and Lilly patent portfolio on empagliflozin covers multiple formulation and use patents, with the earliest expiry dates expected in the late 2020s to early 2030s. Until then, 503A compounding pharmacies in Washington represent one alternative pathway for patients who cannot access the brand-name product affordably.

503A Compounding Pharmacies for Empagliflozin in Washington

Washington state licenses 503A compounding pharmacies under the state Pharmacy Quality Assurance Commission (PQAC) and federal USP standards. A licensed 503A pharmacy in Washington can compound empagliflozin for an individual patient who holds a valid prescription from a licensed Washington prescriber. [12]

503A compounding is patient-specific. The pharmacy cannot produce large batches for general sale. Compounded empagliflozin is typically dispensed as an oral capsule or oral solution and is not bioequivalent-tested against the brand Jardiance tablet. Patients and prescribers should discuss the quality, stability, and regulatory differences before choosing this route.

The FDA's guidance on SGLT2 inhibitor compounding notes that empagliflozin is not on the FDA's 503B outsourcing facility category list, meaning 503B outsourcing facilities cannot produce it in bulk for office use. [2] Only patient-specific 503A compounding is permitted.

Cost for compounded empagliflozin from a Washington 503A pharmacy ranges from approximately $80 to $180 for a 30-day supply depending on dose and formulation, making it meaningfully less expensive than the brand for cash-pay patients.

How Long Does It Take to Get Jardiance in Washington?

The timeline depends on the care pathway chosen.

In-person clinic, insurance with no PA required. The prescriber visit takes one day, the e-prescription processes the same day, and the pharmacy can dispense within 24 hours. Total time: 1-3 days from appointment.

In-person clinic, insurance with PA required. Standard PA review adds 3-5 business days. Urgent PA for a patient with active heart failure hospitalization can process within 24-72 hours under Washington's managed care regulations.

Telehealth, synchronous visit. The provider can issue the prescription the day of the visit if labs are already available. If the patient must first obtain labs at a local draw site, add 1-3 days for results. Total time with available labs: 1-4 days.

Telehealth, asynchronous visit. Form submission to prescription generation: 24-48 hours. Pharmacy processing: 1-2 days. Total: 3-5 business days.

Mail-order pharmacy (90-day supply). Add 3-7 business days shipping after the prescription is received by the mail-order pharmacy. Express shipping options exist with most major mail-order pharmacies.

Patients with HbA1c above 10% or active decompensated heart failure should discuss urgency with their prescriber. In some cases, a prescriber may provide a short-course bridge supply from a local retail pharmacy while the PA or mail-order process completes.

Transferring a Jardiance Prescription to Washington

Washington law permits the transfer of a non-controlled prescription between pharmacies. Because empagliflozin is not a controlled substance, a patient moving to Washington from another state can transfer an active Jardiance prescription to a Washington-licensed pharmacy.

The receiving pharmacy contacts the originating pharmacy, confirms the prescription is valid and has remaining refills, and re-enters it into the Washington dispensing system. The patient does not need a new prescription from a Washington provider solely for the transfer, though they should establish care with a Washington prescriber before refills run out.

For telehealth patients, many national telehealth platforms hold multi-state licenses including Washington and can simply update the preferred pharmacy to a Washington location when the patient relocates.

The Washington State Pharmacy Quality Assurance Commission confirms that transferred prescriptions must include the original date, the name of the original prescriber, and the number of refills remaining. [13] The transfer process typically takes 30-60 minutes but can require up to 24 hours if the originating pharmacy is in a different time zone or uses a less common pharmacy management system.

Dosing and Monitoring After Starting Jardiance

The FDA-approved starting dose for all indications is 10 mg once daily, taken in the morning with or without food. For type 2 diabetes, the dose may be increased to 25 mg once daily to improve glycemic control if tolerated. For heart failure and CKD, the evidence base comes primarily from the 10 mg dose used in EMPEROR-Reduced and EMPA-KIDNEY. [4][5]

Blood pressure typically drops 2-4 mmHg systolic within the first four weeks due to osmotic diuresis and natriuresis. Patients on antihypertensive medications, particularly loop diuretics, should be monitored for orthostatic hypotension. The EMPA-REG OUTCOME trial reported a modest but statistically significant reduction in systolic blood pressure of 3.6 mmHg with empagliflozin versus placebo (P<0.001). [1]

Weight loss of 2-4 kg is typical within the first 12-24 weeks, driven by glycosuria and fluid loss rather than fat mass change. This distinguishes empagliflozin from GLP-1 receptor agonists, which produce greater weight loss primarily through appetite suppression.

Follow-up labs at 3 months post-initiation should include eGFR, BMP, and HbA1c (for diabetes indication). Annual UACR is recommended for CKD patients. [10] Patients should be counseled to hold empagliflozin 3-5 days before any major surgery or prolonged fasting period to reduce the risk of euglycemic diabetic ketoacidosis, a rare but serious adverse event reported with SGLT2 inhibitors. [6]

The 2022 ADA/EASD consensus report states: "SGLT2 inhibitors are recommended for patients with type 2 diabetes and heart failure, chronic kidney disease, or both, independent of HbA1c, to reduce cardiorenal risk." [6] This statement supports prescribing Jardiance even in patients whose HbA1c is well-controlled, provided the cardiorenal indication exists.